multiplexed label-free detection

  • 文章类型: Journal Article
    尽管纳米粒子镜腔的灵敏度很高,等离子体纳米材料的一个重要分支,复杂的制备和读出过程限制了其在生物传感中的广泛应用。或者,液态金属(LMs)结合了流动性和出色的等离子体特性,已成为构建等离子体纳米结构的潜在候选者。在这里,我们提出了一种微流控集成策略来构建基于LM的免疫分析平台,使基于LM的纳米等离子体传感器可用于即时护理(POC)临床生物标志物检测。将可流动的LM引入到蛋白质涂覆的Au纳米颗粒单层上,形成“镜面纳米颗粒”纳米结构,简化了在常规的纳米颗粒镜腔中的制造工艺。当抗体被包被在Au纳米颗粒单层上的抗原捕获时,器件响应生物分子层的厚度和折射率变化,输出肉眼可读信号,具有高灵敏度(检测限:~604fM)和宽动态范围(6阶)。这种新的检测方法,在30分钟内产生定量结果,允许高吞吐量,基于智能手机的SARS-CoV-2抗体检测针对临床血清或血液样本中的多种变体。这些结果为使用LM材料进行POC测试建立了先进的途径,并证明其促进诊断的潜力,各种传染病的监测和流行研究。
    Despite high sensitivity of nanoparticle-on-mirror cavities, a crucial branch of plasmonic nanomaterials, complex preparation and readout processes limit their extensive application in biosensing. Alternatively, liquid metals (LMs) combining fluidity and excellent plasmonic characteristics have become potential candidates for constructing plasmonic nanostructures. Herein, we propose a microfluidic-integration strategy to construct LM-based immunoassay platform, enabling LM-based nanoplasmonic sensors to be used for point-of-care (POC) clinical biomarker detection. Flowable LM is introduced onto protein-coated Au nanoparticle monolayer to form a \"mirror-on-nanoparticle\" nanostructure, simplifying the fabrication process in the conventional nanoparticle-on-mirror cavities. When antibodies were captured by antigens coated on the Au nanoparticle monolayer, devices respond both thickness and refractive index change of biomolecular layers, outputting naked-eye readable signals with high sensitivity (limit of detection: ∼ 604 fM) and a broad dynamic range (6 orders). This new assay, which generates quantitative results in 30 min, allows for high-throughput, smartphone-based detection of SARS-CoV-2 antibodies against multiple variants in clinical serum or blood samples. These results establish an advanced avenue for POC testing with LM materials, and demonstrate its potential to facilitate diagnostics, surveillance and prevalence studies for various infectious diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    新型高通量蛋白质检测技术对于基于人群的大规模SARS-CoV-2抗体检测以及监测针对病毒变体的免疫质量和持续时间是至关重要的。当前的蛋白质微阵列技术严重依赖于标记的转导方法,这些方法需要复杂的仪器和复杂的操作,限制了他们的临床潜力,特别是对于即时护理(POC)应用。这里,我们开发了一种基于厚度感应等离子体标尺的无标签和肉眼可读的微阵列(NRM),在30分钟内实现抗体谱分析。NRM芯片通过有效筛选抗原类型和实验条件,为中和抗体检测提供100%的准确性,并允许在临床样品中针对多种SARS-CoV-2变体的抗体谱分析。我们进一步建立了一个灵活的“条形码”NRM测定与一个简单的基于磁带的操作,实现基于智能手机的有效读出和分析。这些结果证明了高通量蛋白质检测的新策略,并突出了新型蛋白质微阵列技术在实际临床应用中的潜力。
    Novel high-throughput protein detection technologies are critically needed for population-based large-scale SARS-CoV-2 antibody detection as well as for monitoring quality and duration of immunity against virus variants. Current protein microarray techniques rely heavily on labeled transduction methods that require sophisticated instruments and complex operations, limiting their clinical potential, particularly for point-of-care (POC) applications. Here, we developed a label-free and naked-eye readable microarray (NRM) based on a thickness-sensing plasmon ruler, enabling antibody profiling within 30 min. The NRM chips provide 100% accuracy for neutralizing antibody detection by efficiently screening antigen types and experimental conditions and allow for the profiling of antibodies against multiple SARS-CoV-2 variants in clinical samples. We further established a flexible \"barcode\" NRM assay with a simple tape-based operation, enabling an effective smartphone-based readout and analysis. These results demonstrate new strategies for high-throughput protein detection and highlight the potential of novel protein microarray techniques for realistic clinical applications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号